Upgrades For Visteon Corp (NASDAQ:VC), Exane BNP Paribas upgraded the previous rating of Neutral to Outperform. For the first quarter, Visteon had an EPS of $1.09, compared to year-ago quarter EPS of
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market. Grove Collabora

Nasdaq Surges 250 Points; Crude Oil Rises Sharply

07:01pm, Thursday, 07'th Jul 2022 Benzinga
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping 250 points following the release of data on initial jobless claims. The Dow traded up 1.04% to 31,359.65 while th
U.S. stocks traded higher midway through trading, with the Dow Jones jumping more than 200 points following the release of data on initial jobless claims. The Dow traded up 0.77% to 31,275.90 while th
Gainers United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp. American

Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022

02:04pm, Thursday, 07'th Jul 2022 Benzinga
Upgrades For Pacific Premier Bancorp Inc (NASDAQ:PPBI), Raymond James upgraded the previous rating of Outperform to Strong Buy. In the first quarter, Pacific Premier Bancorp showed an EPS of $0.70, co
Truist Securities cut Criteo S.A. (NASDAQ: CRTO) price target from $40 to $35. Criteo shares fell 3.5% to close at $22.92 on Wednesday. Barclays raised Eli Lilly and Company (NYSE: LLY) price targ
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 39.6% to $0.2471 in pre-market trading after declining over 8% on Wednesday. Allena Pharmaceuticals recently announced rescheduling of special

U.S. Stock Futures Edge Higher After Fed Minutes

09:07am, Thursday, 07'th Jul 2022 Benzinga
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade on Thursday following the release of Wednesday’s Fed meeting minutes, suggesting inflation remains the central ban
CytomX Therapeutics Inc's (NASDAQ: CTMX) Phase 2 study of praluzatamab ravtansine in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-non-amplified breast cancer (Arm A
- Study meets primary endpoint of objective response rate in HR+/HER2-non-amplified breast cancer -

NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?

12:33pm, Monday, 27'th Jun 2022 Zacks Investment Research
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that 
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Chau Cheng - VP, IR & Corporate Communications Sean McCarthy - CEO & Chairman Amy

CytomX Therapeutics (CTMX) Q1 2022 Earnings Call Transcript

02:30am, Saturday, 07'th May 2022 The Motley Fool
CTMX earnings call for the period ending March 31, 2022.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE